
    
      This is a phase III, non-inferiority double-blinded, randomized, controlled trial of
      immunogenicity with two groups of participants who will received a seasonal trivalent split,
      inactivated influenza vaccine (A/H1N1; A/H3N2 and B) or an active comparator (licensed
      influenza vaccine).

      A total of about 816 healthy Thai male and female adult volunteers â‰¥ 65 years of age; 408
      participants will be randomized to receive the GPO Tri Fluvac and 408 will receive an active
      comparator (a 1:1 ratio).
    
  